Fairmount Funds Management’s Zenas BioPharma ZBIO Stock Holding History

Fairmount Funds Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.9M	Hold	2,359,025	–	–	3.96%	8
2026 Q1	$46.1M	Buy	2,359,025 +150,000	+7%	+$3.37M	3.33%	10
2025 Q4	$80.2M	Buy	2,209,025 +316,219	+17%	+$10.4M	6.11%	7
2025 Q3	$42M	Hold	1,892,806	–	–	3.78%	13
2025 Q2	$18.3M	Hold	1,892,806	–	–	2.38%	15
2025 Q1	$15M	Hold	1,892,806	–	–	2.32%	13
2024 Q4	$15.5M	Hold	1,892,806	–	–	1.54%	17
2024 Q3	$32M	Buy	+1,892,806	New	+$34M	2.6%	14

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fairmount Funds Management's ZBIO Position: Q2 2026 in Review

Fairmount Funds Management held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 2,359,025 shares worth $59.9M. The position accounts for 3.96% of the portfolio, ranked #8.

Fairmount Funds Management first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $80.2M in Q4 2025. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Fairmount Funds Management held 2,359,025 shares of Zenas BioPharma worth $59.9M as of Q2 2026.
Fairmount Funds Management left its Zenas BioPharma share count unchanged in Q2 2026.
Zenas BioPharma made up 3.96% of Fairmount Funds Management's portfolio in Q2 2026, its #8 holding.
Fairmount Funds Management first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
Fairmount Funds Management's Zenas BioPharma position peaked at $80.2M in Q4 2025.
145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.